Reuters logo
BRIEF-Sucampo Pharma jumps in premarket after FDA OK of sNDA for Rescula
December 12, 2012 / 1:15 PM / in 5 years

BRIEF-Sucampo Pharma jumps in premarket after FDA OK of sNDA for Rescula

NEW YORK, Dec 12 (Reuters) - Sucampo Pharmaceuticals Inc : * Sucampo Pharma jumps 15.5 percent to $5.74 in premarket after the company said the U.S. Food and Drug Administration approved a supplemental new drug application for rescula in patients with open-angle glaucoma or ocular hypertension

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below